ArticleCancer causes & control : CCC2026
Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo examine the prevalence of lifetime ("ever") cannabis and classic psychedelic use, and their co-use among U.S. adults aged ≥ 50 years with versus without a lifetime history of cancer, and to describe variation by cancer type/site among survivors.
methodsWe analyzed pooled 2015-2019 and 2021-2022 National Survey on Drug Use and Health (NSDUH) data of U.S. adults aged ≥ 50 years (Unweighted; n = 42,815 for 2015-2019; n = 21,144 for 2021-2022). Lifetime cannabis and classic psychedelic (LSD, psilocybin, peyote/mescaline) use and cancer history (physician-diagnosed, self-reported) were assessed. Weighted prevalence estimates and 95% CIs were computed, and subgroup analyses by cancer type/site were conducted.
resultsBetween 2015 and 2019, cannabis use was similar among cancer survivors (41.6%, 95% CI 40.0-43.2) and individuals without cancer (42.6%, 95% CI 42.0-43.2, p = 0.21). LSD (8.9, 95% CI 8.1-9.7 vs 10.3, 95% CI 9.8-10.8) and psilocybin (6.4, 95% CI 5.6-7.3 vs 7.7, 95% CI 7.4-8.1) were lower among cancer survivors. Any classic psychedelic use was 11.6% (95% CI 10.6-12.5) among cancer survivors versus 12.9% (95% CI 12.4-13.3) among those without cancer (p < 0.01). Lifetime use of both cannabis and classic psychedelics was lower in cancer survivors (11.2%, 95% CI 10.3-12.1) than in individuals without cancer (12.6%, 95% CI 12.2-13.1, p < 0.01). Between 2021 and 2022, overall group differences were not statistically significant. Across both periods, prevalence varied by cancer type/site, with head and neck, cervical, and hepatobiliary/pancreatic cancer survivors having the highest co-use.
conclusionLifetime cannabis, classic psychedelic, and co-use patterns showed modest differences by cancer history and meaningful variation across cancer type/site. Overall, these findings suggest that substance use patterns among cancer survivors are not uniform and may differ across survivor subgroups.
Indexed as
Identifiers
42017992What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.